

Gibson Dunn Launches Biotech Briefings Blog and New Royalty Finance Tracker to Provide Actionable Insights on Life Sciences Industry Trends

Firm News | April 10, 2025

Gibson Dunn is pleased to announce the launch of [Biotech Briefings](#), a new blog offering timely analysis and commentary on the legal, business, and regulatory issues shaping the life sciences industry. The blog is designed to provide insights for companies, investors, and other industry stakeholders navigating key developments in biopharma, medical devices, diagnostics, and beyond. It will feature expert commentary from leading Gibson Dunn attorneys, on topics including FDA guidance, IP developments, SEC updates, M&A and capital markets trends and activity, royalty finance, collaborations/licensing, litigation and international trade.

“Life sciences businesses operate in a rapidly evolving legal and regulatory landscape, and Biotech Briefings will provide them with actionable insights to help navigate critical issues,” said Ryan A. Murr, Co-Chair of Gibson Dunn’s Life Sciences Group. “From FDA and SEC developments to M&A and financing trends, our goal is to keep clients informed on the most pressing topics shaping the industry.”

In conjunction with the launch of Biotech Briefings, the firm has also introduced the [Gibson Dunn Royalty Finance Tracker](#), a comprehensive database of publicly announced royalty finance transactions among the most active funds in the Life Sciences industry since January 1, 2020. The tracker will serve as a centralized resource, providing a reference point for both current and historical royalty financing trends.

Royalty finance has become an increasingly important tool for biotech companies, universities, and investors, and Gibson Dunn’s Royalty Finance Tracker will provide a one-stop resource for tracking key transactions in the life sciences sector.

About Gibson Dunn’s Life Sciences Group

Gibson Dunn’s Life Sciences Group advises innovative biotechnology, pharmaceutical, medical device and diagnostic companies on a wide range of legal, regulatory, and strategic issues. The firm’s lawyers, many with advanced scientific degrees and hands-on experience in the life sciences industry and regulatory agencies, provide tailored legal guidance throughout the entire life cycle of life sciences companies, from early-stage startups to mature enterprises.

Related Capabilities

[Life Sciences](#)

Related People

[Ryan A. Murr](#)

[Jane M. Love, Ph.D.](#)